

**F. No.50014/03/2020-CDN**  
Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals

Shastri Bhawan, New Delhi  
Dated: 16<sup>th</sup> July, 2021

**Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of June, 2021-reg.**

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of June, 2021 for information.



(N. K. Joshi)

Under Secretary to the Govt. of India

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. PSO to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

**Ministry of Chemicals & Fertilizers**  
**Department of Pharmaceuticals**  
**Monthly Summary for the Month of June, 2021**

Important events for the Month of **June, 2021** are as follows:

**1. IMPORTANT POLICY DECISIONS:**

- i. The operational guidelines of the PLI Scheme for Pharmaceuticals were issued on 01.06.2021. Thereafter, multiple rounds of outreach sessions have been held with the concerned stakeholders including States/UTs, industry associations as well as companies for wide dissemination as well as providing clarifications. Based on industry feedback, the selection criteria has also been suitably modified to provide a level-playing field for API manufacturers vis-a-vis formulation manufacturers. The Department is also in process of compiling and publishing a list of FAQs based on queries raised/clarifications sought by the industry.
- ii. 3 meetings of the Drugs Coordination Committee were also held during the month and inter-alia, recommended allowing restricted exports of Remdesivir in a phased manner; building a buffer of essential covid drugs; systematic monitoring of availability and supply of Conventional Amphotericin B; prioritizing imports by the end of June, 2021; discontinuation of allocation of Conventional Amphotericin-B in view of sluggish demand from States/UTs.
- iii. The Department vide O.M. dated 30.06.2021 to Ministry of Health & Family Welfare has shared a list of medical devices used in management of Covid-19 under Red, Yellow and Green categories based on the lead time of their supply to enable advance planning for building adequate inventory, as part of preparedness to meet any surge in demand in future.

**2. MAJOR ACHIEVEMENTS:**

**I. National Pharmaceutical Pricing Authority (NPPA):**

- i. Retail prices of 15 new medicines have been fixed during June, 2021 bringing cumulative figure to 1548 till June, 2021.
- ii. NPPA vide Gazette Notification No. 216(E) dated 3rd June 2021 has capped the Trade Margin @ 70% on Price to Distributors level with respect to Oxygen Concentrators. The revised MRP for the Oxygen Concentrators with effect from 09th June 2021 has been published vide Office Memorandum dated 09th June 2021.
- iii. Total overcharged amount received during June, 2021 is Rs. 9.96 crores.

**Setting up of 19<sup>th</sup> PMRU:** In June, 2021, PMRU was set-up in the State of Jharkhand. With this, 19 (Nineteen) Price Monitoring and Resource Units (PMRUs) have been set up in the States till date. For setting up of PMRUs in remaining States/UTs, active follow-up is being undertaken with the respective State Governments.

**II. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):**

- i. 102 Jan Aushadhi Kendras under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) were opened during June, 2021 across the country taking cumulative total to 7867.

### III. National Institutes of Pharmaceutical Education and Research (NIPERs):

- i. Out of 146 Research Papers published during the current financial year, 46 papers has been published in June, 2021.
- ii. Out of 7 Patents filed during the current financial year, 2 patents has been filed during the June, 2021.

### IV. COVID-related activities:

- i. **Activities of CDMC:** The COVID Drug Management Cell in DoP continued the work of allocation and monitoring supply of Tocilizumab and Amphotercin-B to Sattes/UTs and Central Govt Hospitals for equitable distribution of the drugs. Weekly monitoring is also being maintained for essential COVID drugs where the Department has not intervened in terms of allocation of the drugs to States/UTs. The allocation of Remdesivir was last done in May, 2021 with a total quantity of 98.87 lakh vials being allocated to States and UTs. On the advise of EG-2, the exports of Remdesivir are being allowed in a calibrated manner while also ensuring that the procurement by HLL for buffer stock is given priority. Close coordination is being maintained by MEA and domestic manufacturers to ensure supply side constraints are resolved.
- ii. **NPPA COVID-19 Control Room Activities:** NPPA has already set up a Control Room (Helpline No.-1800111255/ Email: monitoring-nppa@gov.in) to receive complaints on availability on medicines and is making all out efforts to address the issues promptly by coordinating with the State authorities, manufacturers, marketers and their associations. During the second wave of COVID-19, 1139 complaints were received up to June, 2021.
- iii. **Monitoring Supply of Remdesivir/Tocilizuamb and Amhpotericin to States/UTs across the country:** Daily monitoring of supplies of Amphotericin & Tocilizuamb is being done by NPPA for the allocation made by DoP. Against an allocation of 10.01 lakh vials of Amhpotericin allocated till 30th June 2021 by DoP, supply to the tune of 8.12 lakh vials was made to the State/UT Governments. Similarly, supply of 93.85 lakh vials of Remesivir was made against an allocation of 98.87 lakh vials.

### V. Budget Expenditure:

In the Financial Year 2021-22, the total budget allocated to Department of Pharmaceuticals Rs. 470.41 Cr and the details of expenditure incurred are as below:

(Rs. in Crore)

Total Budget allocated	Expenditure incurred (as on 30.06.2021)	Expenditure incurred in the month of June, 2021
Rs. 470.41	Rs. 88.55	23.64

2. The details of grievances during the **June, 2021** are as under:

No. of grievances at the start of the month	No. of grievances received during the month	No. of grievances disposed	No. of grievances pending at end of the month
210	317	340	187

3. FDI proposals:-

(a) Pending at beginning of the month	:-	11
(b) Received during the month	:-	6
(c) Disposed of during the month	:-	0
(d) Pending at end of the month	:-	17

\*\*\*\*\*